- Stocks
- Pharma & Healthcare
- Vaidya Sane Ayu
Vaidya Sane Ayu share price
NSE: MADHAVBAUGPharma & Healthcare
Vaidya Sane Ayu at a glance
Vaidya Sane Ayu (NSE: MADHAVBAUG) closed at ₹161.10 on 16 Oct 2026. With a market capitalisation of ₹169 Cr, it ranks 2376th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
Its return on equity was 12.5% in FY26. Over the past year the share price has fallen 43.1%. Its 52-week range is ₹147.00 (8 Sep 2026) to ₹335.00 (26 Dec 2025); the last close is 51.9% below the high. Promoters held 66.34% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹169 CrRank 2376 on NSE
- Price to book
- 2.44×FY26
- ROE
- 12.5%FY26
- ROCE
- 12.5%FY26
- Debt to equity
- 0.04FY26
- Net profit margin
- 5.0%FY26
- Book value / share
- ₹68.16FY26
- 52-week high
- ₹335.0026 Dec 2025
- 52-week low
- ₹147.008 Sep 2026
- 1-year return
- −43.1%
- RSI (14-day)
- 42.2
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −4.11% | −5.1% | +1.4% | −7.9% | −43.1% |
Vaidya Sane Ayu financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹99 Cr | ₹99 Cr | ₹90 Cr | ₹107 Cr |
| Operating profit | ₹6 Cr | ₹3 Cr | ₹11 Cr | ₹11 Cr |
| Net profit | ₹5 Cr | ₹2 Cr | ₹7 Cr | ₹9 Cr |
| EPS (₹) | ₹5.00 | ₹2.00 | ₹7.00 | ₹9.00 |
| Cash from operations | ₹0 Cr | −₹4 Cr | ₹11 Cr | ₹5 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹3 Cr |
| Shareholders' equity | ₹40 Cr | ₹56 Cr | ₹63 Cr | ₹72 Cr |
Vaidya Sane Ayu shareholding pattern
| Holder | 31 Mar 2024 | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 66.34% | 66.34% | 66.34% | 66.34% | 66.34% | 66.34% |
| Non-institutions | 33.66% | 33.66% | 33.66% | 33.45% | 33.66% | 33.66% |
Vaidya Sane Ayu vs peers
The listed Pharma & Healthcare companies nearest to Vaidya Sane Ayu by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| NOVELIXNovelix Pharma | — | — | — | ₹181 Cr | — | — |
| MEDICOMedico Remedies | ₹21.68 | −2.03% | −56.8% | ₹180 Cr | 13.7 | — |
| TAKETake Solutions | ₹11.96 | −5.23% | −25.9% | ₹177 Cr | 41.2 | — |
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| NATCAPSUQNatural Capsules | ₹162.00 | +1.25% | −32.2% | ₹169 Cr | — | — |
| PANCHSHEELPanchsheel Org | — | — | — | ₹159 Cr | — | — |
Ask anything about Vaidya Sane Ayu
Pivot answers on the live chart with evidence you can check, and tests strategies against MADHAVBAUG's own history. Try: “Why has MADHAVBAUG moved over the last three months?” · “Backtest a 50-day moving-average crossover on MADHAVBAUG over five years” · “Compare MADHAVBAUG with NOVELIX on margins and valuation”
Frequently asked questions about Vaidya Sane Ayu
What is the share price of Vaidya Sane Ayu today?
Vaidya Sane Ayu (NSE: MADHAVBAUG) last closed at ₹161.10 on 16 Oct 2026. Its 52-week high is ₹335.00 and its 52-week low is ₹147.00.
What is the market cap of Vaidya Sane Ayu?
Vaidya Sane Ayu's market capitalisation is ₹169 Cr (₹169 Cr) at the 19 Oct 2026 close, ranking 2376th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Vaidya Sane Ayu?
Return on equity was 12.5% in FY26 and return on capital employed was 12.5% in FY26 (consolidated figures).
Is Vaidya Sane Ayu a debt-free company?
Vaidya Sane Ayu is close to debt-free: its debt-to-equity ratio was 0.04 in FY26.
How has Vaidya Sane Ayu stock performed over the last year?
Vaidya Sane Ayu's share price has fallen 43.1% over the past year, −7.9% over three months and +1.4% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Vaidya Sane Ayu?
As of 31 Mar 2026: promoters 66.34%, non-institutions 33.66%.
Who are Vaidya Sane Ayu's competitors?
The listed Pharma & Healthcare companies closest to Vaidya Sane Ayu by market cap are Novelix Pharma, Medico Remedies, Take Solutions, Bal Pharma, Natural Capsules and Panchsheel Org.
Is Vaidya Sane Ayu a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vaidya Sane Ayu's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MADHAVBAUG against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 16 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text